Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Summit Hotel Properties, Inc. (INN-PF)

NYSE - Nasdaq Real Time Price. Currency in USD
17.500.00 (0.00%)
At close: 11:33AM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close17.28
Open17.37
Bid16.12 x 800
Ask27.99 x 900
Day's Range17.73 - 17.73
52 Week Range16.04 - 26.00
Volume101
Avg. Volume8,928
Market CapN/A
Beta (5Y Monthly)1.98
PE Ratio (TTM)N/A
EPS (TTM)-0.58
Earnings DateN/A
Forward Dividend & Yield1.47 (8.49%)
Ex-Dividend DateNov 15, 2022
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for INN-PF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Summit Hotel Properties, Inc. 5
    SVC: Raising target price to $7.00SERVICE PROPERTIES TRUST has an Investment Rating of SELL; a target price of $7.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • Newsfile

    Innocan Pharma Signs a First Consulting Agreement to Commercialize its Pharmaceutical IP in the Veterinary Field

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - December 2, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce that it has signed a consulting agreement with Benitz Consulting LLC ("Benitz Consulting") to assist the Company's commercialization of IP in the veterinary field. The principal of Benitz Consulting

  • Newsfile

    Innocan Pharma Reports Q3 2022 Results with 700% Increase in Revenues Compared to Q3 2021

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - November 29, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to report its financial results for the three and nine months ended September 30, 2022. "We delivered encouraging results in the third quarter, with revenue growth and ar

  • Newsfile

    Mr. Givi Topchishvili to Join Innocan Pharma's Advisory Committee

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - November 18, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to announce the addition of Givi Topchishvili, to Innocan's Advisory Committee, as a business strategy adviser, focused on commercializing of healthcare innovations. Giv

Advertisement
Advertisement